Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.

Travere Therapeutics, Inc.

Travere Therapeutics is a biopharmaceutical company that identifies, develops, and delivers life-changing therapies to people living with rare disease.

COM:TRAVERE